Berkley Renewables holds 91,812 of the issued and outstanding shares of RepliCel Life Sciences Inc., with the option to acquire more shares.

RepliCel is a regenerative medicine company developing autologous* cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function.

The company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The company is also developing a proprietary, next-generation injection device (RCI) for optimal clinical delivery. Each condition is related to a deficit of a specific cell type which management believes is critical to the restoration of normal function..

For more information, please visit

*Using a patient's own cells

Copyright © 2021 by Berkley Renewables Inc.   All rights reserved worldwide.
For more information, send questions and comments to
This page was created on Sat Oct 30, 2021 at 4:57:23 AM Pacific Time.